Drug treatment for spinal muscular atrophy type I

Wendy M J Bosboom, Alexander F J E Vrancken, Leonard H. Van Den Berg, John H J Wokke, Susan T. Iannaccone

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Spinal muscular atrophy (SMA) is caused by degeneration of anterior horn cells, which leads to progressive muscle weakness. Children with SMA type I will never be able to sit without support and usually die by the age of two years. There are no known efficacious drug treatments that influence the disease course. Objectives: To evaluate if drug treatment is able to slow or arrest the disease progression of SMA type I, and to assess if such therapy can be given safely. Drug treatment for SMA type II and III will be will be the topic of a separate Cochrane review. Search strategy: We searched the Cochrane Neuromuscular Disease Group Trials Register (September 30 2008, The Cochrane Library (Issue 3, 2008), MEDLINE (January 1966 to June 2008), EMBASE (January 1980 to June 2008), ISI (January 1988 to June 2008), and ACP Journal Club (January 1991 to June 2008). Selection criteria: All randomized or quasi-randomized trials that examined the efficacy of drug treatment for SMA type 1 were sought. Participants had to fulfil clinical criteria and, in studies including genetic analysis to confirm the diagnosis, have a deletion or mutation of the SMN1 gene (5q11.2-13.2) The primary outcome measure was to be time from birth until death or full time ventilation. Secondary outcome measures were to be development of rolling, sitting or standing within one year after the onset of treatment, and adverse events attributable to treatment during the trial period. Data collection and analysis: Two authors (WB and AV) independently reviewed and extracted data from all potentially relevant trials. For included studies pooled relative risks and pooled weighted standardized mean differences were to be calculated to assess treatment efficacy Main results: One small randomized-controlled study comparing riluzole treatment to placebo for SMA type 1 was identified and included in the review. Regarding the primary outcome measure three of seven children treated with riluzole were still alive at the age of 30, 48 and 64 months, whereas all three children in the placebo group died, but the difference was not statistically significant. Regarding the secondary outcome measures none of the patients in the riluzole or placebo group developed the ability to roll, sit or stand, and no adverse effects were observed. Authors' conclusions: No drug treatment for SMA type I has been proven to have significant efficacy.

Original languageEnglish (US)
Article numberCD006281
JournalCochrane Database of Systematic Reviews
Issue number1
DOIs
StatePublished - 2009

Fingerprint

Spinal Muscular Atrophies of Childhood
Riluzole
Pharmaceutical Preparations
Outcome Assessment (Health Care)
Placebos
Therapeutics
Anterior Horn Cells
Spinal Muscular Atrophy
Neuromuscular Diseases
Sequence Deletion
Muscle Weakness
MEDLINE
Patient Selection
Libraries
Ventilation
Disease Progression
Parturition

Keywords

  • Child, preschool
  • Humans
  • Infant
  • Neuroprotective agents [*therapeutic use]
  • Randomized controlled trials as topic
  • Riluzole [*therapeutic use]
  • Spinal muscular atrophies of childhood [*drug therapy]

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Cite this

Bosboom, W. M. J., Vrancken, A. F. J. E., Van Den Berg, L. H., Wokke, J. H. J., & Iannaccone, S. T. (2009). Drug treatment for spinal muscular atrophy type I. Cochrane Database of Systematic Reviews, (1), [CD006281]. https://doi.org/10.1002/14651858.CD006281.pub2

Drug treatment for spinal muscular atrophy type I. / Bosboom, Wendy M J; Vrancken, Alexander F J E; Van Den Berg, Leonard H.; Wokke, John H J; Iannaccone, Susan T.

In: Cochrane Database of Systematic Reviews, No. 1, CD006281, 2009.

Research output: Contribution to journalArticle

Bosboom, Wendy M J ; Vrancken, Alexander F J E ; Van Den Berg, Leonard H. ; Wokke, John H J ; Iannaccone, Susan T. / Drug treatment for spinal muscular atrophy type I. In: Cochrane Database of Systematic Reviews. 2009 ; No. 1.
@article{0a7fba52370b46c881f8855619cb87b2,
title = "Drug treatment for spinal muscular atrophy type I",
abstract = "Background: Spinal muscular atrophy (SMA) is caused by degeneration of anterior horn cells, which leads to progressive muscle weakness. Children with SMA type I will never be able to sit without support and usually die by the age of two years. There are no known efficacious drug treatments that influence the disease course. Objectives: To evaluate if drug treatment is able to slow or arrest the disease progression of SMA type I, and to assess if such therapy can be given safely. Drug treatment for SMA type II and III will be will be the topic of a separate Cochrane review. Search strategy: We searched the Cochrane Neuromuscular Disease Group Trials Register (September 30 2008, The Cochrane Library (Issue 3, 2008), MEDLINE (January 1966 to June 2008), EMBASE (January 1980 to June 2008), ISI (January 1988 to June 2008), and ACP Journal Club (January 1991 to June 2008). Selection criteria: All randomized or quasi-randomized trials that examined the efficacy of drug treatment for SMA type 1 were sought. Participants had to fulfil clinical criteria and, in studies including genetic analysis to confirm the diagnosis, have a deletion or mutation of the SMN1 gene (5q11.2-13.2) The primary outcome measure was to be time from birth until death or full time ventilation. Secondary outcome measures were to be development of rolling, sitting or standing within one year after the onset of treatment, and adverse events attributable to treatment during the trial period. Data collection and analysis: Two authors (WB and AV) independently reviewed and extracted data from all potentially relevant trials. For included studies pooled relative risks and pooled weighted standardized mean differences were to be calculated to assess treatment efficacy Main results: One small randomized-controlled study comparing riluzole treatment to placebo for SMA type 1 was identified and included in the review. Regarding the primary outcome measure three of seven children treated with riluzole were still alive at the age of 30, 48 and 64 months, whereas all three children in the placebo group died, but the difference was not statistically significant. Regarding the secondary outcome measures none of the patients in the riluzole or placebo group developed the ability to roll, sit or stand, and no adverse effects were observed. Authors' conclusions: No drug treatment for SMA type I has been proven to have significant efficacy.",
keywords = "Child, preschool, Humans, Infant, Neuroprotective agents [*therapeutic use], Randomized controlled trials as topic, Riluzole [*therapeutic use], Spinal muscular atrophies of childhood [*drug therapy]",
author = "Bosboom, {Wendy M J} and Vrancken, {Alexander F J E} and {Van Den Berg}, {Leonard H.} and Wokke, {John H J} and Iannaccone, {Susan T.}",
year = "2009",
doi = "10.1002/14651858.CD006281.pub2",
language = "English (US)",
journal = "The Cochrane database of systematic reviews",
issn = "1361-6137",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Drug treatment for spinal muscular atrophy type I

AU - Bosboom, Wendy M J

AU - Vrancken, Alexander F J E

AU - Van Den Berg, Leonard H.

AU - Wokke, John H J

AU - Iannaccone, Susan T.

PY - 2009

Y1 - 2009

N2 - Background: Spinal muscular atrophy (SMA) is caused by degeneration of anterior horn cells, which leads to progressive muscle weakness. Children with SMA type I will never be able to sit without support and usually die by the age of two years. There are no known efficacious drug treatments that influence the disease course. Objectives: To evaluate if drug treatment is able to slow or arrest the disease progression of SMA type I, and to assess if such therapy can be given safely. Drug treatment for SMA type II and III will be will be the topic of a separate Cochrane review. Search strategy: We searched the Cochrane Neuromuscular Disease Group Trials Register (September 30 2008, The Cochrane Library (Issue 3, 2008), MEDLINE (January 1966 to June 2008), EMBASE (January 1980 to June 2008), ISI (January 1988 to June 2008), and ACP Journal Club (January 1991 to June 2008). Selection criteria: All randomized or quasi-randomized trials that examined the efficacy of drug treatment for SMA type 1 were sought. Participants had to fulfil clinical criteria and, in studies including genetic analysis to confirm the diagnosis, have a deletion or mutation of the SMN1 gene (5q11.2-13.2) The primary outcome measure was to be time from birth until death or full time ventilation. Secondary outcome measures were to be development of rolling, sitting or standing within one year after the onset of treatment, and adverse events attributable to treatment during the trial period. Data collection and analysis: Two authors (WB and AV) independently reviewed and extracted data from all potentially relevant trials. For included studies pooled relative risks and pooled weighted standardized mean differences were to be calculated to assess treatment efficacy Main results: One small randomized-controlled study comparing riluzole treatment to placebo for SMA type 1 was identified and included in the review. Regarding the primary outcome measure three of seven children treated with riluzole were still alive at the age of 30, 48 and 64 months, whereas all three children in the placebo group died, but the difference was not statistically significant. Regarding the secondary outcome measures none of the patients in the riluzole or placebo group developed the ability to roll, sit or stand, and no adverse effects were observed. Authors' conclusions: No drug treatment for SMA type I has been proven to have significant efficacy.

AB - Background: Spinal muscular atrophy (SMA) is caused by degeneration of anterior horn cells, which leads to progressive muscle weakness. Children with SMA type I will never be able to sit without support and usually die by the age of two years. There are no known efficacious drug treatments that influence the disease course. Objectives: To evaluate if drug treatment is able to slow or arrest the disease progression of SMA type I, and to assess if such therapy can be given safely. Drug treatment for SMA type II and III will be will be the topic of a separate Cochrane review. Search strategy: We searched the Cochrane Neuromuscular Disease Group Trials Register (September 30 2008, The Cochrane Library (Issue 3, 2008), MEDLINE (January 1966 to June 2008), EMBASE (January 1980 to June 2008), ISI (January 1988 to June 2008), and ACP Journal Club (January 1991 to June 2008). Selection criteria: All randomized or quasi-randomized trials that examined the efficacy of drug treatment for SMA type 1 were sought. Participants had to fulfil clinical criteria and, in studies including genetic analysis to confirm the diagnosis, have a deletion or mutation of the SMN1 gene (5q11.2-13.2) The primary outcome measure was to be time from birth until death or full time ventilation. Secondary outcome measures were to be development of rolling, sitting or standing within one year after the onset of treatment, and adverse events attributable to treatment during the trial period. Data collection and analysis: Two authors (WB and AV) independently reviewed and extracted data from all potentially relevant trials. For included studies pooled relative risks and pooled weighted standardized mean differences were to be calculated to assess treatment efficacy Main results: One small randomized-controlled study comparing riluzole treatment to placebo for SMA type 1 was identified and included in the review. Regarding the primary outcome measure three of seven children treated with riluzole were still alive at the age of 30, 48 and 64 months, whereas all three children in the placebo group died, but the difference was not statistically significant. Regarding the secondary outcome measures none of the patients in the riluzole or placebo group developed the ability to roll, sit or stand, and no adverse effects were observed. Authors' conclusions: No drug treatment for SMA type I has been proven to have significant efficacy.

KW - Child, preschool

KW - Humans

KW - Infant

KW - Neuroprotective agents [therapeutic use]

KW - Randomized controlled trials as topic

KW - Riluzole [therapeutic use]

KW - Spinal muscular atrophies of childhood [drug therapy]

UR - http://www.scopus.com/inward/record.url?scp=70249106694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70249106694&partnerID=8YFLogxK

U2 - 10.1002/14651858.CD006281.pub2

DO - 10.1002/14651858.CD006281.pub2

M3 - Article

C2 - 19160274

AN - SCOPUS:70249106694

JO - The Cochrane database of systematic reviews

JF - The Cochrane database of systematic reviews

SN - 1361-6137

IS - 1

M1 - CD006281

ER -